- Home
- MGNX vs MIST Comparison
MGNX vs MIST Comparison
Compare MGNX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MIST
- Stock Information
- Founded
- MGNX 2000
- MIST 2003
- Country
- MGNX United States
- MIST Canada
- Employees
- MGNX N/A
- MIST N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- MGNX Health Care
- MIST Health Care
- Exchange
- MGNX Nasdaq
- MIST Nasdaq
- Market Cap
- MGNX 87.7M
- MIST 89.8M
- IPO Year
- MGNX 2013
- MIST N/A
- Fundamental
- Price
- MGNX $1.33
- MIST $1.71
- Analyst Decision
- MGNX Hold
- MIST Strong Buy
- Analyst Count
- MGNX 9
- MIST 2
- Target Price
- MGNX $5.33
- MIST $7.50
- AVG Volume (30 Days)
- MGNX 2.0M
- MIST 658.4K
- Earning Date
- MGNX 08-05-2025
- MIST 08-07-2025
- Dividend Yield
- MGNX N/A
- MIST N/A
- EPS Growth
- MGNX N/A
- MIST N/A
- EPS
- MGNX N/A
- MIST N/A
- Revenue
- MGNX $154,050,000.00
- MIST N/A
- Revenue This Year
- MGNX N/A
- MIST N/A
- Revenue Next Year
- MGNX N/A
- MIST N/A
- P/E Ratio
- MGNX N/A
- MIST N/A
- Revenue Growth
- MGNX 255.31
- MIST N/A
- 52 Week Low
- MGNX $0.99
- MIST $0.63
- 52 Week High
- MGNX $5.77
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- MGNX 41.45
- MIST 60.15
- Support Level
- MGNX $1.33
- MIST $1.67
- Resistance Level
- MGNX $2.17
- MIST $1.80
- Average True Range (ATR)
- MGNX 0.17
- MIST 0.08
- MACD
- MGNX -0.02
- MIST -0.01
- Stochastic Oscillator
- MGNX 2.38
- MIST 43.24
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).